CLAIMS

1. Stabilising formulation for polyclonal immunoglobulins G compositions, characterised in that the formulation includes a sugar alcohol, glycine in a concentration between 7 g/l and 10 g/l and a non-ionic detergent in a concentration between 20 and 50 ppm, in order to be suitable for the stabilisation of immunoglobulins G compositions in liquid form and in lyophilised form.

2. Stabilising formulation according to claim 1 consisting of the said sugar alcohol, glycine and non-ionic detergent.

3. Formulation according to claim 1, characterized in that the sugar alcohol is mannitol.

4. Formulation according to claim 3, characterized in that the concentration of mannitol is between 30 g/l and 50 g/l.

5. Polyclonal immunoglobulins G composition in liquid form comprising, as stabiliser, a stabilising formulation consisting of a sugar alcohol, glycine in a concentration between 7 g/l and 10 g/l and a non-ionic detergent in a concentration between 20 and 50 ppm.

6. Polyclonal immunoglobulins G composition in lyophilised form, obtained by lyophilisation of a polyclonal immunoglobulins G composition and a stabilising formulation including a sugar alcohol, glycine in a concentration between 7 g/l and 10 g/l and a non-ionic detergent in a concentration between 20 and 50 ppm.

7. Polyclonal immunoglobulins G composition according to claim 5, characterized in that it includes an amount of polymers less than 0.3 % after a 6 months storage period at room temperature.

8. Polyclonal immunoglobulins G

composition according to claim 6, characterized in that it includes an amount of polymers less than 0.3 % after a 12 months storage period at room temperature or for 6 months at 40°C.

9. Polyclonal immunoglobulins G composition according to claim 5, characterized in that the composition includes an amount of dimers less than 7 % after a 24 months storage period at 4°C.

10. Use of a stabilising formulation according to claim 2 as stabiliser, for polyclonal immunoglobulins G compositions in liquid form obtained directly by fractioning of human plasma.

11. Use of a stabilising formulation according to claim 1, for stabilisation of polyclonal immunoglobulins G compositions in lyophilised form.

12. Use of a stabilising formulation according to claim 1 for stabilisation of polyclonal immunoglobulins G compositions in liquid form obtained after reconstitution in a suitable aqueous medium of polyclonal immunoglobulins G compositions in lyophilised form.